benzo[1,3]dioxole-2,2-dicarboxylic acid | 25260-30-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: benzo[1,3]dioxole-2,2-dicarboxylic acid
• 英文别名: 1,3-Benzodioxole-2,2-dicarboxylic acid
• CAS: 25260-30-4
• 化学式: C₉H₆O₆
• 分子量: 210.143
• InChiKey: PELSWIPEICPCTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  93.1
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Aryloxypropanolamine derivatives, method of preparation and applications thereof
  申请人：VIRBAC SA

  公开号：US20020019440A1

  公开（公告）日：2002-02-14

  The invention concerns aryloxypropanolamnine derivatives having at least an anti-diabetic and anti-fat activity and their methods of preparation and applications, particularly as human and veterinary medicine and animal food additive. These derivatives comply with the general formula (I) in which R 2 represents one of the following groups: —CH 2 —, —CH 2 —CH 2 , —CH(CH 3 )—CH 2 —C(CH 3 )—CH—, —C(CH 3 ) 2 —CH 2 — or a bond; Q represents: (i) a phenyl radical 3,4-substituted alkylene dioxy determining with the phenyl radical, a non-substituted benaodioxane unit, a non-substituted benzodioxol unit, or a 2-substituted benzodioxol unit, (ii) a phenyl radical 3 and/or 4-substituted, by a O—(CH 2 ) x —COOR 5 group, (iii) a condensed polycyclic hydrocarbon comprising at least two condensed cycles, (iv) a cyclic hydrocarbon system, optionally cross-linked, and constituting a cycloalkane comprising 1, 2 or 3 cycles. 1

  该发明涉及至少具有抗糖尿病和抗脂肪活性的芳氧丙醇胺衍生物及其制备和应用方法，特别是作为人类和兽医药物以及动物食品添加剂。这些衍生物符合以下一般式(I)，其中R2代表以下其中一种基团：—CH2—，— — —，—CH(CH3)— —C( )—CH—，—C( )2— —或键；Q代表：(i) 一个苯基3,4-取代烷二氧基基团，与苯基形成非取代苯二氧杂环单元、非取代苯二氧杂环单元或2-取代苯二氧杂环单元，(ii) 一个苯基3和/或4-取代，通过O—( )x—COOR5基团，(iii) 至少包含两个缩合环的多环脂环烃，(iv) 一个环烃系统，可选地交联，并构成包含1、2或3个环的环戊烷。
• Compositions and methods for inducing adipose tissue cell death
  申请人：——

  公开号：US20040235922A1

  公开（公告）日：2004-11-25

  Pharmaceutical compositions, methods for increasing the rate of apoptosis in adipose tissue cells, and methods of reducing adipose tissue mass in a host, are described. One exemplary pharmaceutical composition, among others, includes at least one catecholamine in combination with a pharmaceutically acceptable carrier. The catecholamine is present in a dosage level effective to increase the rate of apoptosis in adipose tissue cells in a host.

  药物组合物，增加脂肪组织细胞凋亡速率的方法，以及减少宿主体内脂肪组织质量的方法被描述。其中一种示例药物组合物包括至少一种儿茶酚胺与一种药用可接受载体的组合。儿茶酚胺以有效剂量存在，用于增加宿主体内脂肪组织细胞的凋亡速率。
• Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0455006A2

  公开（公告）日：1991-11-06

  The present invention discloses substituted 1,3-benzodioxoles which possess anti-diabetic and/or anti-hyperglycemic and/or anti-obesity properties in humans and other animals.

  本发明公开了取代的 1,3-苯并二恶茂，它们对人类和其他动物具有抗糖尿病和/或抗高血糖和/或抗肥胖的特性。
• Aminocycloalkanobenzodioxoles as beta-3 selective adrenergic agents
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0608568A1

  公开（公告）日：1994-08-03

  The invention is antiobesity/antidiabetic/beta-3 agonists of the formula wherein the substituents Ro, R₁, R₄, R₄', R₅, R₆ or n are as defined in the specification.

  本发明是式中的抗肥胖/抗糖尿病/β-3 激动剂 其中取代基 Ro、R₁、R₄、R₄'、R₅、R₆ 或 n 如说明书中所定义。
• Novel dicarboxylic acid derivatives
  申请人：BIOPROJET

  公开号：EP1650186B1

  公开（公告）日：2008-06-04